Andrew Anzalone was restless. It was late fall, 2017. The year was winding down, and so was his MD/PhD program at Columbia. Trying to figure out what was next in his life, he’d taken to long, leaf-strewn walks in the West Village. One night as he paced up Hudson Street, his stomach filled with La Colombe coffee and his mind with Crispr gene editing papers, an idea began to bubble through the caffeine brume inside his brain.

Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.

Advertisement